Edison Investment Research - MGC Pharmaceuticals (MXC) MGC Pharmaceuticals - Rapid prescription growth in Australia and the UK

Report

Edison Investment Research

Sean Conroy

MGC Pharmaceuticals - Rapid prescription growth in Australia and the UK

Since beginning in earnest in August this year, 1,000 prescriptions for MGCâ€™s phytocannabinoid products (CannEpil and MXP100) have been issued in Australia and the UK. Double the number of prescriptions were issued in October compared to September. Cash receipts for the quarter ending 30 September were A$413,000, with additional revenue of more than A$400,000 from recent sales expected to be received following the end of the quarter.

04/11/2019 6 EN

Underlying

MGC Pharmaceuticals

MGC Pharmaceuticals as various inerest in seven prospective gold assets located in the Republic of Senegal, being the Lingokoto, Bouroubourou, Wassadou North and South, Woye, Garaboureya South and Balakonko gold projects.

See profile

AU000000MXC6 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

proactiveinvestors

Funding to progress CannEpil, with CimetrA data soon

MGC Pharmaceuticals is an emerging pharmaceutical company selling plant-derived, medicinal products in the UK, Ireland and Australia. Core marketed products are the food supplement, ArtemiC, promoted to help reduce COVID-19 symptoms, and medicinal cannabis products sold in Australia, UK and Ireland

April 21, 2023 April 21, 2023 1 EN

EQS Group AG

EQS-News: MGC Pharmaceuticals delivers its largest-ever order

EQS-News: MGC Pharmaceuticals Ltd MGC Pharmaceuticals delivers its largest-ever order 08.12.2022 / 14:46 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 08.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com Language:...

December 8, 2022 December 8, 2022 1 EN

proactiveinvestors

MGC Pharma funded to drive projects

MGC Pharmaceuticals Ltd sells plant-derived, medicinal products in the UK, Ireland and Australia. Core marketed products are a food supplement, ArtemiC, to help overcome COVID-19 infection and medicinal cannabis products sold in Australia, UK and Ireland. A dramatic new initiative is the new medica

August 16, 2022 August 16, 2022 1 EN

Filtronic - Agreement with SpaceX drives upgrades

Filtronic has signed a strategic partnership and commercial agreement with SpaceX which includes a production order worth £15.8m and warrants that could be exercised for up to 10% of existing share capital. Filtronic announced its first orders from SpaceX in January 2023, although the customer was unnamed at that point. Since then, SpaceX has placed orders totalling $43m (including yesterday’s order) for products to support the build out of its Starlink low Earth orbit (LEO) satellite constellation. The scale of these orders is such that we upgrade our forecasts, with the larger impact on FY25...

1h / 28m 1h / 28m 1 EN

Richard Williamson

Richard Williamson

Checkit - Signposting the path to profitability

In a tough trading environment, Checkit managed to grow FY24 revenue by 17% and reduce EBITDA losses by nearly half. The company has had a positive start to FY25 with new contract wins and the launch of a new module. Focus on growth from its existing customer base combined with strict cost control is helping Checkit to make steady progress towards its target of positive EBITDA and cash generation in FY27.

1h / 47m 1h / 47m 1 EN

Richard Williamson

Richard Williamson

EML Payments - Growth cap lifted in the UK

EML Payments announced that on 23 April the Financial Conduct Authority (FCA) in the UK lifted the new customer restriction for Prepaid Financial Services Limited (PFSL), which had been in place since October 2022. With the appropriate structure and risk management controls now in place, PFSL can focus on growing the business. This marks another positive step forward for the group, after exiting PFS Card Services Ireland Limited (PFS), agreeing to sell Sentenial and finalising the settlement liabilities for the PFS acquisition.

1h / 59m 1h / 59m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN